References
- Bray,
F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., &
Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of
incidence and mortality worldwide for 36 cancers in 185 countries. CA:
A Cancer Journal for Clinicians.2018; 68(6):394–424.
- National Comprehensive Cancer
Network. Clinical Practice Guidelines in Oncology (NCCN guidelines):
Non-small cell lung cancer. Version 6. 8
17.
https://www.nccn.org/professionals/physician_gls/default.aspx.
Accessed 5 July 2020.
- Felip E, Rosell R, Maestre JA,
et al. Preoperative chemotherapy plus surgery versus surgery plus
adjuvant chemotherapy versus surgery alone in early-stage non-
small-cell lung cancer. J Clin Oncol 2010;28:3138-45.
- Berry MF, Coleman BK, Curtis LH, Worni M, D’Amico TA, Akushevich I.
Berry MF, Coleman BK, Curtis LH, Worni M, D’Amico TA, Akushevich I.
Benefit of adjuvant chemotherapy after resection of stage II
(T1-2N1M0) non-small cell lung cancer in elderly patients. Ann Surg
Oncol. 2015;22(2):642-648.
- Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin
evaluation: a pooled analysis by the LACE Collaborative Group. J Clin
Oncol. 2008;26(21):3552-3559.
- Arriagada R, Bergman B, Dunant
A, et al. Cisplatin-based adjuvant chemotherapy in patients with
completely resected non-small-cell lung cancer. N Engl J Med.
2004;350(4):351-360.
- Pu, C. Y., & Yendamuri, S.
Neoadjuvant versus adjuvant chemotherapy for resectable non-small cell
lung cancer debate revisited. Journal of Thoracic Disease.
2019;11(12):5646–5648.
- Subramanian, M. P., & Puri, V.
Neoadjuvant vs. adjuvant chemotherapy in locally advanced non-small
cell lung cancer-is timing everything? Journal of Thoracic Disease.
2019;11(12): 5674–5676.
- NSCLC Meta-analysis
Collaborative Group. Preoperative chemotherapy for non-small-cell lung
cancer: a systematic review and meta-analysis of individual
participant data. Lancet, 2014;383:1561-71.
- Brandt, W. S., Yan, W., Zhou,
J., Tan, K. S., Montecalvo, J., Park, B. J., … Jones, D. R.
Outcomes Following Neoadjuvant or Adjuvant Chemotherapy for cT2-4N0-1
Non-Small Cell Lung Cancer: A Propensity-Matched Analysis. J Thorac
Cardiovasc Surg. 2020;157(2):743–753.
- Westeel, V., Quoix, E.,
Puyraveau, M., Lavolé, A., Braun, D., Laporte, S., Milleron, B. A
randomised trial comparing preoperative to perioperative chemotherapy
in early-stage non-small-cell lung cancer (IFCT 0002 trial). European
Journal of Cancer. 2013;49(12):2654–2664.
- Lim E, Harris G, Patel A, Adachi
I, Edmonds L, Song F. Preoperative versus postoperative chemotherapy
in patients with resectable non-small cell lung cancer: systematic
review and indirect comparison meta-analysis of randomized trials. J
Thorac Oncol. 2009;4(11):1380-1388.
- Zhang XN, Huang L. Neoadjuvant
chemotherapy followed by surgery versus upfront surgery in
non-metastatic non-small cell lung cancer: systematic review and
meta-analysis of randomized controlled trials. Oncotarget.
2017;8(52):90327-90337.
- Tran AQ, Erim DO, Sullivan SA,
et al. Cost effectiveness of neoadjuvant chemotherapy followed by
interval cytoreductive surgery versus primary cytoreductive surgery
for patients with advanced stage ovarian cancer during the initial
treatment phase. Gynecol Oncol. 2018;148(2):329-335.
- Cole, A. L., Barber, E. L.,
Gogate, A., Tran, A. Q., & Wheeler, S. B. Economic Analysis of
Neoadjuvant Chemotherapy Versus Primary Debulking Surgery for Advanced
Epithelial Ovarian Cancer Using an Aggressive Surgical Paradigm.
International Journal of Gynecological Cancer. 2018; 28(6):
1077–1084.
- Rowland, M. R., Lesnock, J. L., Farris, C., Kelley, J. L., & Krivak,
T. C. Cost-utility comparison of neoadjuvant chemotherapy versus
primary debulking surgery for treatment of advanced-stage ovarian
cancer in patients 65 years old or older. American Journal of
Obstetrics and Gynecology. 2015; 212(6):763.e1-763.e8.
- Poonawalla, I. B., Lairson, D.
R., Chan, W., Piller, L. B., & Du, X. L. Cost-Effectiveness of
Neoadjuvant Chemotherapy versus Primary Surgery in Elderly Patients
with Advanced Ovarian Cancer. Value in Health. 2015; 18(4):387–395.
- Onisim, A., Achimas-Cadariu, P.,
Iancu, M., Puscas, E., Bodog, A., & Vlad, C. Clinical outcomes and
cost-effectiveness of primary treatment of ovarian cancer in
North-Western Romania. Journal of BUON. 2019; 24(3):982–990.
- Forde
GK, Chang J, Ziogas A. Cost-effectiveness of primary debulking surgery
when compared to neoadjuvant chemotherapy in the management of stage
IIIC and IV epithelial ovarian cancer. Clinicoecon Outcomes Res.
2016;8:397-406.
- Himmel, M., Hartmann, M., & Guntinas-Lichius, O. Cost effectiveness
of neoadjuvant chemotherapy in locally advanced operable head and neck
cancer followed by surgery and postoperative radiotherapy: A Markov
model-based decision analysis. Oncology (Switzerland).
2013;84(6):336–341.
- Denduluri, N., Patt, D. A.,
Wang, Y., Bhor, M., Li, X., Favret, A. M., Lyman, G. H. (2015). Dose
delays, dose reductions, and relative dose intensity in patients with
cancer who received adjuvant or neoadjuvant chemotherapy in community
oncology practices. JNCCN Journal of the National Comprehensive Cancer
Network. 2015; 13(11):1383–1393.
- Grutters, J. P. C., Joore, M.
A., Wiegman, E. M., Langendijk, J. A., De Ruysscher, D., Hochstenbag,
M., Pijls-Johannesma M. (2010). Health-related quality of life in
patients surviving non-small cell lung cancer. Thorax.
2010;65(10):903–907.
- Paracha N, Abdulla A, MacGilchrist KS. Systematic review of health
state utility values in metastatic non-small cell lung cancer with a
focus on previously treated patients. Health Qual Life Outcomes.
2018;16(1):179.
- Handorf,
E. A., McElligott, S., Vachani, A., Langer, C. J., Bristol Demeter,
M., Armstrong, K., & Asch, D. A. Cost Effectiveness of Personalized
Therapy for First-Line Treatment of Stage IV and Recurrent Incurable
Adenocarcinoma of the Lung. Journal of Oncology Practice.
2012;8(5):267–274.
- Lugg, S. T., Agostini, P. J.,
Tikka, T., Kerr, A., Adams, K., Bishay, E., Naidu, B.
Long-term impact of developing a
postoperative pulmonary complication after lung surgery. Thorax.
2016;71(2):171–176.
- Xin, L., Jufang, S., Jian, Y.,
& Wanqing, C. Influencing Factors of Hospitalization Expenses of
Surgical Lung Cancer Patients:An Analysis of 5222 Cases. China
Cancer. 2019:28(12):922–926.
- National Institutes of Health,
National Cancer Institute: Common Terminology Criteria for Adverse
Events (CTCAE).
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50.
Accessed 5 July 2020.
- Chinese Society Oncology Cancer
(CSCO). Guideline of Chinese Society Oncology Cancer (CSCO) Primary
Lung Cancer. People’s Medical Publishing House; 2019.
- Shanghai municipal health
commission. Medical programs fee
schedule (MPFS). http://wsjkw.sh.gov.cn/ylsfbz/index.html. 2017.
Accessed 5 July 2020.
- Briggs, AH., Claxton, K.,
Sculpher, MJ. Decision modelling for health economic evaluation.
Oxford University Press; 2006.
- Fagotti A, Ferrandina G,
Vizzielli G, Fanfani F, Gallotta V, Chiantera V, et al. Phase III
randomised clinical trial comparing primary surgery versus neoadjuvant
chemotherapy in advanced epithelial ovarian cancer with high tumor
load (SCORPION trial): Final analysis of peri-operative outcome. Eur J
Cancer. 2016; 59:22–33.